Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for CDXS
1.77
-0.04 (-2.21%)
Apr 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.77 - 1.82
52 week 1.24 - 2.89
Open 1.82
Vol / Avg. 16,729.00/88,039.00
Mkt cap 67.96M
P/E     -
Div/yield     -
EPS -1.08
Shares 38.40M
Beta 1.69
Inst. own 41%
May 5, 2014
Q1 2014 Codexis, Inc. Earnings Release (Estimated) Add to calendar
Mar 11, 2014
Q4 2013 Codexis, Inc. Earnings Conference Call - Webcast
Mar 11, 2014
Q4 2013 Codexis, Inc. Earnings Release
Feb 11, 2014
Codexis, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -103.03% -129.39%
Operating margin -103.42% -128.90%
EBITD margin - -96.57%
Return on average assets -62.84% -52.02%
Return on average equity -85.24% -68.88%
Employees 154 -
CDP Score - -

Address

200 Penobscot Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Codexis, Inc., is a producer of custom industrial enzymes. The Company's products enable processes for the manufacture of biofuels, bio-based chemicals and pharmaceutical ingredients. As of December 31, 2011, the Company was developing its CodeXyme cellulase enzymes to convert non-food plant material, which the Company calls cellulosic biomass, into sugars, which can then be converted into renewable fuels and chemicals. The Company intends to market CodeXyme cellulase enzymes to chemicals manufacturers worldwide. The Company is also developing its own manufacturing processes for certain specialty and commodity bio-based chemicals. The first of these products is CodeXol detergent alcohols. Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products, such as shampoos, liquid soaps and laundry detergents. In March 2014, Intrexon Corp acquired laboratory operations in Budapest, Hungary from Codexis, Inc.

Officers and directors

Thomas R. Baruch Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
David D. O'Toole CPA Chief Financial Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Peter Seufer-Wasserthal Ph.D. Senior Vice President - Pharmaceuticals
Age: 51
Bio & Compensation  - Reuters
Matt Tobin Senior Vice President - Research & Development
Age: 51
Bio & Compensation  - Reuters
Pedro Isamu Mizutani Director
Age: 54
Bio & Compensation  - Reuters
Patrick Y. Yang Ph.D. Director
Age: 65
Bio & Compensation  - Reuters
Byron L. Dorgan Independent Director
Age: 70
Bio & Compensation  - Reuters
Alexander A. Karsner Independent Director
Age: 46
Bio & Compensation  - Reuters